Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Biomea Fusion Inc market cap is $35.47M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Biomea Fusion Inc 52 week high is $2.24 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Biomea Fusion Inc 52 week low is $0.4634 as of November 18, 2026.
Biomea Fusion Inc stock price today is $0.5222.
Biomea Fusion Inc stock price yesterday was $0.488.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Biomea Fusion Inc's P/E ratio is -1.58.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Biomea Fusion Inc P/B ratio is 4.6752.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Biomea Fusion Inc 50-day moving average is $1.07.